Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

OraSure Awarded $13.6M From BARDA to Advance COVID-19 Rapid Test

by Global Biodefense Staff
September 23, 2021
OraSure Awarded $13.6M From BARDA to Advance COVID-19 Rapid Test

Credit: OraSure via MedicalCountermeasures.gov

BARDA renews collaboration with OraSure Technologies to support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

BARDA and OraSure Technologies, Inc. are partnering again, this time to advance their rapid antigen test for SARS-CoV-2 to U.S. Food and Drug Administration (FDA) 510(k) clearance.

InteliSwab™ is a simple “swab, swirl, and see” test that uses an integrated swab to self-collect a sample from the lower nostrils. The result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed. It has three Emergency Use Authorizations from the Food and Drug Administration for professional point-of-care use, prescription (Rx) home use, and over-the-counter (OTC) use.

BARDA supported development of the OraSure InteliSwab test from inception through Emergency Use Authorization (EUA) for over-the-counter (InteliSwab COVID-19 Rapid Test), prescription home use (InteliSwab COVID-19 Rapid Test Rx), and professional point-of-care use (InteliSwab COVID-19 Rapid Test Pro). These tests received EUA in June 2021.

The 510(k) clearance and CLIA waiver for this test will ensure InteliSwab continues to be available on the market even after the public health emergency is declared over.

The InteliSwab test targets the detection of all clinically relevant SARS-CoV-2 variants of concern, as qualified by the U.S. Centers for Disease Control and Prevention (CDC). Currently there are no rapid point-of-care antigen tests available with 510(k) clearance.

DoD Procures InteliSwab COVID-19 Rapid Tests for Nearly 25,000 Sites

The Defense Logistics Agency earlier this month awarded OraSure a procurement contract for its InteliSwab™ COVID-19 Rapid Test for over-the-counter use, which the Defense Logistics Agency estimated to have a value of $205 million.

Under the terms of the contract, OraSure will provide its InteliSwab™ COVID-19 Rapid Test to up to 25,000 sites throughout the United States as part of the National pandemic response and the tests will be funded by the U.S. federal government. The contract will run from October 2021 through September 2022.

Sources: BARDA, OraSure Technologies, Inc., Defense.gov

Tags: ASPRAwardsBARDACOVID-19Editor PickEmergency Use AuthorizationHHSPOC DiagnosticsPublic Health EmergencySARS

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC